Bagel, J., A. W. Armstrong, R. B. Warren, K. A. Papp, D. Thaçi, A. Menter, J. Cather, M. Augustin, L. Hippeli, C. Daamen, and C. E. Griffiths. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy by Prior Treatment in the Phase 3 POETYK PSO-1 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s117, doi:10.25251/skin.7.supp.117.